Troglitazone combination therapy in obese type 2 diabetic patients poorly controlled with α-glucosidase inhibitors

Journal of International Medical Research

Volumn 27, Issue 2, 1999, Pages 53-64

  Bando, Y ^a   Ushiogi, Y ^a   Okafuji, K ^a   Toya, D ^a   Tanaka, N ^a   Fujisawa, M ^a  

^a FUKUI KEN SAISEIKAI HOSPITAL   (Japan)

Author keywords

Combined therapy; Troglitazone; Type 2 diabetes; glucosidase inhibitor

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LACTATE DEHYDROGENASE; ORAL ANTIDIABETIC AGENT; TRIACYLGLYCEROL; TROGLITAZONE; VOGLIBOSE;

ADULT; AGED; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EDEMA; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

EID: 0032802627     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/030006059902700201     Document Type: Article

References (27)

1. Balfour JA, McTavish D: Acarbose. An update of its pharmacology and therapeutic use in diabetes mellitus. Drugs 1993; 4: 1025-1054.
2. Horii S, Fukase H, Matsuo T, Kameda Y, et al: Synthesis and alphaD-glucosidase inhibitory activity of N-substituted valiolamine derivatives as potential oral antidiabetic agents. J Med Chem 1986; 29: 1038-1046.
3. Hoffman CA, Colca JA: New oral thiazolidinedione antidiabetic agents act as insulin sensitizers. Diabetes Care 1992; 15: 1075-1078.
4. Leonhardt W, Hanefeld M, Fischer S, et al: Beneficial effects on serum lipids in non-insulin dependent diabetics by acarbose treatment. Arzneimittelforschung 1991; 1: 735-438.
5. Yamada N, Akanuma Y, Murase T, et al: Clinical evaluation of a new oral hypoglycaemic drug CS-045 in patients with non-insulin dependent diabetes mellitus accompanying hypertriglyceridemia (in Japanese, English abstract). J Clin Ther Med 1993; 9 (Suppl 3): 165-178.
6. Toyota T, Satoh J, Takebe K, et al: Results of long-term combined therapy with CS-045 and insulin in patients with insulin dependent or non-insulin-dependent diabetes mellitus (in Japanese, English abstract). J Clin Ther Med 1997; 13: 1533-1561.
7. Kosaka K, Kuzuya T, Akanuma Y, et al: Clinical evaluation of a new oral hypoglycaemic drug CS-045 in patients with non-insulin dependent diabetes mellitus poorly controlled by sulphonylureas - a double-blind, placebo-controlled study (in Japanese, English abstract). J Clin Ther Med 1993; 9: 95-126.
8. Uttenthal LO, Ukponmwan OO, Wood SM et al: Long-term effects of intestinal alpha-glucosidase inhibition on postprandial glucose, pancreatic and gut hormone responses and fasting serum lipids in diabetics on sulfonylureas. Diabet Med 1986; 3: 155-160.
9. Coniff RF, Shapiro JA, Seaton TB, et al. A double-blind placebo-controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type II diabetes. Diabetes Care 1995; 18: 928-932.
10. Kaneko T, Suzuki N, Inoue K, et al: Clinical evaluation of combined therapy with an insulin sensitizer, AD4833 and voglibose in type 2 diabetes patients - a non-blind, phase III study (in Japanese). Jap J Clin Exp Med 1997; 74: 1540-1556.
11. Akanuma Y, Kosaka K, Kuzuya T, et al: Long-term study of a new oral hypoglycaemic drug CS-045 in patients with non-insulin dependent diabetes mellitus (in Japanese, English abstract). J Clin Ther Med 1993: 9 (Suppl 3): 119-141.
12. Carrascosa M Pascual F, Aresti S: Acarbose-induced acute severe hepatotoxity. Lancet 1997; 349: 698-699.
13. Kuramoto T, Shimizu N, Toda G: Liver dysfunction associated with troglitazone (Noscal) (in Japanese, English abstract). J Clin Ther Med 1998; 14: 461-466.
14. Fukuda M: Clinical arrangement of classification of diabetic retinopathy. Tohoku J Exp Med 1983; 141 (Suppl): 331-335.
15. Matthews DR, Hosker JP: Homeostasis model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin concentrations in men. Diabetologia 1985; 28: 412-419.
16. Odaka H, Satoh Y, Amano N, et al: Antidiabetic actions of insulin sensitizer alone or in combination with α-glucosidase inhibitor in genetically obese-diabetic rats, Wistar fatty (in Japanese, English abstract). Jpn Pharmacol Ther 1997; 25: 355-361.
17. Fujiwara T, Yoshida S, Yoshioka T, et al: Characterization of a new oral antidiabetic agent CS-045: studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 1988; 37: 1549-1558.
18. Suter SL, Nolan JJ, Wallace P, et al: Metabolic effects of new oral hypoglycaemic agent CS-045 in NIDDM patients. Diabetes Care 1992; 15: 193-203.
19. Fujiwara T, Yoshioka S, Yoshioka T, et al: Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 1988; 37: 1549-1558.
20. Picard F, Deshaies Y: Postprandial serum lipids and lipoprotein lipase are acutely altered in rats by the alpha-glucosidase inhibitor acarbose. Horm Metab Res 1996; 28: 377-380.
21. Davidson J, Cohn JS: Triglycerides: a risk factor for coronary heart disease. Atherosclerosis 1996; 124: S57-S64.
22. Chiasson JL: The effect of acarbose on insulin sensitivity in patients with impaired glucose tolerance. Diabet Med 1996; 13: S23-S24.
23. Chawla A, Schwarz EJ, Dimaculangan DD, et al: Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology 1994; 135: 798-800.
24. Lehmann JM, Moore LB, Smith-Oliver TA, et al: An antidiabetic thiazolidione is a high affinity ligand for peroxisome proliferative activated receptor-gamma (PPAR gamma). J Biol Chem 1995; 270: 12953-12956.
25. Inoue I, Takahashi K, Katayama S, et al: Effect of troglitazone (CS-045) and bezafibrate on glucose tolerance, fiver glycogen synthase activity, and β-oxidation in fructose-fed rats. Metabolism 1995; 44: 1626-1630.
26. Hallukou S, Doare L, Foufelle F, et al: Pioglitazone induces in vivo adipocytes differentiation in the obese Zucker fa/fa rat. Diabetes 1997; 46: 1393-1399.
27. Okuno A, Tamemoto H, Tobe K, et al: Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 1998; 101: 1354-1361.